Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,530 | 1,660 | 16.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |
---|---|---|---|---|
Fr | Armata Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | |
ARMATA PHARMACEUTICALS Aktie jetzt für 0€ handeln | ||||
21.05. | ARMP Soars 72% in a Month Following Infectious Disease Study Success | 2 | Zacks | |
20.05. | Armata stock price target raised to $9 at H.C. Wainwright | 6 | Investing.com | |
19.05. | Armata links bacteria-killing virus to clinical responses in phase 2 trial | 15 | FierceBiotech | |
19.05. | Armata reports positive results for phage therapy trial | 6 | Investing.com | |
19.05. | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | 122 | PR Newswire | |
14.05. | Armata Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | |
14.05. | Armata Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | |
14.05. | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update | 118 | PR Newswire | |
01.05. | Armata Pharmaceuticals erhält zusätzliche Finanzierung vom US-Verteidigungsministerium | 7 | Investing.com Deutsch | |
01.05. | Armata Pharmaceuticals, Inc. - 8-K, Current Report | 7 | SEC Filings | |
02.04. | Armata Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | |
21.03. | Armata Pharmaceuticals GAAP EPS of -$0.23, revenue of $1.2M | 9 | Seeking Alpha | |
20.03. | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update | 759 | PR Newswire | |
12.03. | Armata Pharmaceuticals sichert sich Kredit in Höhe von 10 Millionen US-Dollar | 5 | Investing.com Deutsch | |
12.03. | Armata Pharmaceuticals announces $10M secured credit agreement with Innoviva | 5 | Seeking Alpha | |
12.03. | Armata Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | |
19.12.24 | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa ... | 133 | PR Newswire | |
19.12.24 | Armata Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | |
13.11.24 | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update | 135 | PR Newswire |